Gilead, Xilio Therapeutics Ink Exclusive Licensing Agreement to Develop Early Phase Tumor-Activated IL-12

Deal aims to commercialize XTX301 for treating advanced solid tumors by leveraging Xilio’s tumor-activated immuno-oncology therapies.

Source link
#Gilead #Xilio #Therapeutics #Ink #Exclusive #Licensing #Agreement #Develop #Early #Phase #TumorActivated #IL12